GlassScriptPhysician profile
Marc Wilson
NPI 1508443771
$2,812.95
in general payments reported to CMS, 2019-2025
31 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $842 · 2023: $717 · 2024: $776 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.50 | 2022-2025 | |
| Novo Nordisk INC | $283.70 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $272.49 | 2021-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $240.43 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.50 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $157.93 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.42 | 2021-2022 | |
| Pfizer INC. | $131.92 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.12 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.04 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.38 | 2022-2023 | |
| Astellas Pharma US INC | $62.25 | 2022-2024 | Veozah, Myrbetriq |
| Horizon Therapeutics Plc | $46.09 | 2022 | |
| Dexcom, INC. | $44.18 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $41.87 | 2024-2025 | Flucelvax, Fluad |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $41.24 | 2022 | |
| Alkermes, INC. | $39.11 | 2023 | Lybalvi |
| Janssen Pharmaceuticals, INC | $30.00 | 2022-2023 | Xarelto |
| Exact Sciences Corporation | $28.50 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $28.13 | 2025 | Gemtesa |
| Kyowa Kirin, INC. | $27.81 | 2025 | |
| Paratek Pharmaceuticals, INC. | $27.36 | 2021 | |
| Glaxosmithkline, LLC. | $26.17 | 2025 | Trelegy Ellipta |
| Gilead Sciences, INC. | $20.54 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.75 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.46 | 2023 | Nuedexta |
| Avanir Pharmaceuticals, INC. | $16.81 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.50 | 2022 | |
| Merck Sharp & Dohme LLC | $16.32 | 2022 | |
| Abbott Laboratories | $15.47 | 2025 | Freestyle Libre |
| Currax Pharmaceuticals LLC | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.